

## LIST OF TABLE

Table 1. Top 10 countries for number of people with diabetes (Age 20-79 years).....	4
Table 2. Current marketed drugs for the treatment of hyperglycemia and insulin resistance.....	5
Table 3. Current therapy for the treatment of dyslipidemia. ....	6
Table 4. Summary of structure, homology and tissue expression of PPARs.....	13
Table 5. Pharmacological effects of PPAR $\alpha$ , $\gamma$ and $\delta$ activation.....	19
Table 6. Natural and synthetic ligands of PPAR $\alpha$ , $\gamma$ and $\beta/\delta$ .....	24
Table 7. Dual, Pan and Partial PPAR agonist .....	35
Table 8. <i>In vitro</i> hPPAR transactivation activity of test compounds ( <b>11a-k</b> ). ....	48
Table 9. <i>Anti</i> -hyperlipidemic and <i>anti</i> -hyperglycemic activities of compound <b>11c</b> in <i>db/db</i> mice <sup>a</sup> . 50	
Table 10. <i>In vivo</i> anti-hyperlipidemic activity of compound <b>11c</b> in HC fed SD rats <sup>a</sup> . ....	50
Table 11. Mean pharmacokinetic parameters <sup>a</sup> of <b>11c</b> in fasted male wistar rats. ....	51
Table 12. <i>In vitro</i> hPPAR transactivation activity of compounds <b>17a-i</b> . ....	55
Table 13. <i>In vivo</i> efficacy of the compound <b>17a</b> , <b>17g</b> and <b>17i</b> in <i>db/db</i> mice <sup>a</sup> .....	57
Table 14. <i>In vitro</i> hPPAR transactivation and TG reducing activity of <b>22a-j</b> . ....	64
Table 15. <i>In vitro</i> hPPAR transactivation and TG reducing activity of <b>27a-e</b> . ....	66
Table 16. <i>In vitro</i> hPPAR transactivation and TG reducing activity of <b>33a-b</b> . ....	68
Table 17. Mean pharmacokinetic parameters of <b>27a</b> in fasted <i>male Wistar</i> rat. ....	68
Table 18. <i>In vivo</i> efficacy of the compound <b>27a</b> in <i>db/db</i> mice <sup>a</sup> . ....	69
Table 19. <i>Anti</i> -hyperlipidemic and <i>anti</i> -hyperglycemic activity of <b>27a</b> in male <i>Zucker fa/fa</i> rat <sup>a</sup> .....	69
Table 20. <i>Anti</i> -hyperlipidemic activity of compound <b>27a</b> in HF-HC hamsters <sup>a</sup> . ....	70
Table 21. <i>In vitro</i> hPPAR transactivation and TG reducing activity of <b>46,51,54,57,66a-b,70&amp;73</b> . 80	
Table 22. <i>Anti</i> -Hyperglycemic and <i>anti</i> -hyperlipidemic activities of <b>70</b> in <i>db/db</i> mice <sup>a</sup> .....	80
Table 23. <i>Anti</i> -hyperlipidemic activities of compounds <b>70</b> in HF-HC hamsters <sup>a</sup> .....	81

## LIST OF FIGURES

Figure 1. Changes in lipoprotein metabolism associated with type 2 diabetes mellitus and the metabolic syndrome. ....	2
Figure 2 : Schematic representation of the functional domains of PPARs.....	8
Figure 3: A. PPAR $\alpha$ cocrystalized with GW-409544 (PDB entry no: IK7L); B. PPAR $\gamma$ cocrystalized with Rosiglitazone (PDB entry no: 2PRG); C. PPAR $\delta$ cocrystalized with D32 (PDB entry no: 3GZ9) .....	9
Figure 4: Molecular mechanism for transcriptional activation by PPAR isoforms .....	10
Figure 5: Structures of natural ligands of PPAR $\alpha$ .....	21
Figure 6: Chemical structures of PPAR $\alpha$ agonists.....	22
Figure 7: Natural ligand for PPAR $\gamma$ .....	24
Figure 8: Chemical structures of PPAR $\gamma$ agonists .....	25
Figure 9: Natural PPAR $\beta/\delta$ ligand.....	27
Figure 10: PPAR $\delta$ agonist.....	28
Figure 11: Chemical structures of PPAR $\alpha/\gamma$ dual agonists.....	30
Figure 12: pan PPAR agonists .....	33
Figure 13: PPAR $\gamma$ partial agonist.....	34
Figure 14: PPAR $\delta/\beta$ partial agonist.....	36
Figure 15: Design of dioxane carboxylic acids .....	38
Figure 16: Identification of lipophilic part for selective PPAR $\alpha$ agonistic activity.....	38
Figure 17: Structural development of potent hPPAR $\alpha/\gamma$ dual agonist (I) for weak and partial hPPAR $\alpha$ agonists.....	40
Figure 18: Designing of novel PPAR agonist .....	42
Figure 19: Replacement of phenyl ring with naphthalene as central aromatic spacer. ....	43
Figure 20: Oximes containing 1,3 dioxane- <i>r</i> -2-carboxylic acid.....	44
Figure 21: (A) ORTEP diagram of <b>6a</b> with atom numbering scheme (30% probability factor for the thermal ellipsoids). (B) ( <i>cis</i> ).....	46
Figure 22: A) ORTEP diagram of <b>6b</b> with atom numbering scheme (30% probability factor for the thermal ellipsoids). (B) ( <i>trans</i> ).....	46

Figure 23 : Molecular docking of <b>11c</b> into PPAR $\alpha$ (A) and $\gamma$ (B) binding pockets:H-bond interactions with amino acids are shown in dashed lines.....	52
Figure 24: Structure-Activity Relationship of 5-substituted indole.....	53
Figure 25: Molecular docking of <b>17a</b> into PPAR $\alpha$ (A) and $\gamma$ (B) binding pockets:H-bond interactions with amino acids are shown in dashed lines.....	58
Figure 26: Structural modifications in the lipophilic tail region.....	59
Figure 27: Structure of <b>27a</b> and <b>27b</b> determined by single crystal X-ray diffraction: (A) ORTEP diagram with atom numbering scheme (B) Image generated by Mercury software 2.3 version. ..	62
Figure 28: Transactivation data toward hPPAR $\alpha$ by <b>27a</b> , <b>27b</b> and <b>WY14643</b> . ..	67
Figure 29: A. Molecular docking of <b>27a</b> (Z isomer) and B. <b>27b</b> (E isomer) into PPAR $\alpha$ binding pockets: H-bond interactions with amino acids are shown in dashed lines. ....	71
Figure 30: Chemical structure of Netoglitazone and PPAR coagonists.....	72
Figure 31: Molecular docking of <b>70</b> into PPAR $\alpha$ (A) and $\gamma$ (B) and $\delta$ (C) binding pockets and molecular docking of Netoglitazone into PPAR $\alpha$ (A1) and $\gamma$ (B2) and $\delta$ (C1) binding pockets:H-bond interactions with amino acids are shown in dashed lines.....	82

## ABBREVIATIONS

<b>11<math>\beta</math>-HSD1</b>	11beta-hydroxysteroid dehydrogenase type 1
<b>Acrp 30</b>	Adipocyte –related complement protein 30
<b>AF</b>	Activation function
<b>ATP</b>	Adenosine triphosphate
<b>AUC</b>	Area under the curve (AUC)
<b>BF<sub>3</sub>.Et<sub>2</sub>O</b>	Boron trifluoride diethyl etherate
<b>BMI</b>	Body Mass Index
<b>CAP</b>	c-Cb1-associated protein
<b>CHD</b>	Coronary heart disease
<b>Cmax</b>	Maximum concentration
<b>CPT</b>	Carnitine palmitoyltransferase
<b>Cs<sub>2</sub>CO<sub>3</sub></b>	Cesium carbonate
<b>CVD</b>	Cardiovascular disease
<b>DBD</b>	DNA binding domain
<b>DIBAL-H</b>	Diisobutylaluminium hydride
<b>DMF</b>	Dimethylformamide
<b>DR</b>	Direct repeat
<b>FATP</b>	Fatty acid transporter protein
<b>FFA</b>	Free fatty acids
<b>HbA1c</b>	Hemoglobin A1c
<b>HDL-C</b>	High density lipoprotein cholesterol
<b>ICAM-1</b>	Intercellular Adhesion Molecule 1
<b>IDL</b>	Intermediate-density lipoproteins

<b>IFN<math>\gamma</math></b>	Interferon gamma
<b>IL</b>	Interleukin
<b>K<sub>2</sub>CO<sub>3</sub></b>	Potassium carbonate
<b>LAH</b>	Lithium aluminium hydride
<b>LBD</b>	Ligand binding domain
<b>LDL-C</b>	Low density lipoprotein cholesterol
<b>LiOH·H<sub>2</sub>O</b>	Lithium hydroxide monohydrate
<b>LPL</b>	Lipoprotein lipase
<b>LXR-<math>\alpha</math></b>	Liver X receptor alpha
<b>MCP-1</b>	Monocyte chemotactic protein-1
<b>MMP-9</b>	Matrix metalloproteinase 9
<b>MS</b>	Metabolic syndrome
<b>NCoR</b>	Nuclear receptor co-repressor
<b>NEFAs</b>	Non esterified (free) fatty acids
<b>NF-<math>\kappa</math>B</b>	Nuclear Factor-kappaB
<b>NRs</b>	Nuclear receptors
<b>ORTEP</b>	Oak Ridge Thermal Ellipsoid Plot
<b>PAI1</b>	Plasminogen activator inhibitor type 1
<b>PBP</b>	PPAR binding protein
<b>Pd/C</b>	Palladium on carbon
<b>PK</b>	Pharmacokinetics
<b>PPARs</b>	Peroxisome proliferator-activated receptors
<b>PPRE</b>	Peroxisome proliferator-activated receptor (PPAR) response element

<b>RXR</b>	Retinoid X receptor
<b>SAM</b>	Swiss albino mice
<b>SAR</b>	Structure–activity relationship
<b>SMRT</b>	Retinoid and thyroid hormone receptors
<b>SRC</b>	Steroid receptor co-activator
<b>T<sub>1/2</sub></b>	Half life of elimination
<b>T2DM</b>	Type-2 diabetes mellitus
<b>TG</b>	Triglyceride
<b>THF</b>	Tetrahydrofuran
<b>T<sub>max</sub></b>	Time taken to reach maximum concentration
<b>TNF<math>\alpha</math></b>	Tumor necrosis factor alpha
<b>TZDs</b>	Thiazolidinediones
<b>UCP</b>	Uncoupling protein
<b>VCAM-1</b>	Vascular cell adhesion molecule-1
<b>VLDL</b>	Very low density lipoprotein
<b>WAT</b>	White adipose tissue